secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2025-09-23T23:59:59+00:00
Accession:  0001171843-25-006027
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SEED Therapeutics closes $30M Series A-3, FDA clears IND for lead RBM39 degrader
--------------------------------------------------------------------------------

- Second close of $6M completes $30M Series A-3; BeyondSpring to own ~38.03% on as-converted basis.
- FDA cleared IND for ST-01156 (RBM39); first-in-human trial expected Q1 2026.
- SEED has received ~$60M in equity and payments from Eli Lilly and Eisai partnerships.
- BeyondSpring expects to continue consolidating SEED as it retains substantive control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325006027/0001171843-25-006027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325006027/f8k_092225.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer